

PRIOR AUTHORIZATION CRITERIA

BRAND NAME
(generic)

CIALIS 2.5 mg, 5 mg
(tadalafil)

Status: CVS Caremark Criteria

Type: Initial Prior Authorization with Quantity Limit

POLICY

FDA-APPROVED INDICATIONS

Erectile Dysfunction

Cialis is indicated for the treatment of erectile dysfunction (ED).

Benign Prostatic Hyperplasia

Cialis is indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH).

Erectile Dysfunction and Benign Prostatic Hyperplasia

Cialis is indicated for the treatment of ED and the signs and symptoms of BPH (ED/BPH).

Limitation of Use

If Cialis is used with finasteride to initiate BPH treatment, such use is recommended for up to 26 weeks because the incremental benefit of Cialis decreases from 4 weeks until 26 weeks, and the incremental benefit of Cialis beyond 26 weeks is unknown.

COVERAGE CRITERIA

The requested drug will be covered with prior authorization when the following criteria are met:

- The requested drug is being prescribed for daily use for symptomatic benign prostatic hyperplasia (BPH)
[Note: Examples of signs and symptoms of BPH are incomplete emptying, weak stream, straining, urinary frequency, intermittency, or urgency.]

Quantity Limits apply.

30 tablets/25 days or 90 tablets/75 days*

* The duration of 25 days is used for a 30-day fill period and 75 days is used for a 90-day fill period to allow time for refill processing.

REFERENCES

1. Cialis [package insert]. Indianapolis, IN: Eli Lilly and Company; February 2018.
2. Lexicomp Online, AHFS DI (Adult and Pediatric) Online. Hudson, OH: Wolters Kluwer Clinical Drug Information, Inc. <http://online.lexi.com/>. Accessed April 2020.
3. Micromedex (electronic version). Truven Health Analytics, Greenwood Village, Colorado, USA. <http://www.micromedexsolutions.com/>. Accessed April 2020.
4. American Urological Association Guideline Management of Benign Prostatic Hyperplasia (BPH). 2010. Available at [https://www.auanet.org/guidelines/benign-prostatic-hyperplasia-\(bph\)-guideline/benign-prostatic-hyperplasia-\(2010-reviewed-and-validity-confirmed-2014\)](https://www.auanet.org/guidelines/benign-prostatic-hyperplasia-(bph)-guideline/benign-prostatic-hyperplasia-(2010-reviewed-and-validity-confirmed-2014)). Accessed April 2020.
5. Roehrborn CG, Kaminetsky JC, Auerbach SM et al. Changes in peak urinary flow and voiding efficiency in men with signs and symptoms of benign prostatic hyperplasia during once daily tadalafil treatment. *BJU Int* 2010;105:502-507.